Daiichi Sankyo exon-skips into ultra-orphan ring with DMD alliance
This article was originally published in Scrip
Perhaps encouraged by strong global investor and clinician interest in companies developing new drugs for very rare orphan diseases, Daiichi Sankyo has unveiled plans for a new Japanese joint venture specializing in antisense oligonucleotides for the treatment of Duchenne muscular dystrophy (DMD).
You may also be interested in...
Several companies have DMD drug candidates waiting in the wings to follow Sarepta’s Exondys 51 into the commercial market after FDA approval of the exon-skipping therapy, which could be the backbone for future combination treatment regimens.
A busy stretch of deal-making across Asia all includes transactions involving Innovent, Alector, Ono, Numab, Alphamab, 3DMed, Healios, Athersys, Laekna, Novartis, Asahi Kasei, SBI Biotech, Glenmark, Hindustan Unilever, Hanlim, Alteogen, Ildong, Evotec, AJU Pharm, Ribomec, Tyligand, Context
New potential topical therapy in dermatitis space set to move towards Japan approval submission based on positive new results.